Craft

Immunome

Stock Price

$12.2

2024-10-29

Market Capitalization

$746.5 M

2024-10-28

Revenue

$14 M

FY, 2023

Immunome Summary

Company Summary

Overview
Immunome is a biotech company focused on cancer immunotherapies fueled by the human immune system. Its immunotherapy discovery engine leverages “the most highly educated” immune systems from patients who have already learned how to fight off their disease. The proprietary technology platform enables the simultaneous discovery of antigens and the patient-derived, native antibodies that target those antigens.
Type
Public
Status
Active
Founded
2008
HQ
Exton, PA, US | view all locations
Website
http://immunome.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Sandra G. Stoneman

    Sandra G. Stoneman, Chief Legal Officer and Corporate Secretary

    • Matthew K. Robinson

      Matthew K. Robinson, Senior Vice President, R&D

      LocationsView all

      1 location detected

      • Exton, PA HQ

        United States

        665 Stockton Dr #300

      Immunome Financials

      Summary Financials

      Revenue (Q2, 2024)
      $2.4M
      Net income (Q2, 2024)
      ($36.1M)
      Cash (Q2, 2024)
      $165.3M
      EBIT (Q2, 2024)
      ($40.0M)
      Enterprise value
      $583.6M

      Footer menu